论文部分内容阅读
目的：探讨恶性血液病患者血清可溶性白细胞介素６受体（ｓＩＬ－６Ｒ）的临床价值。方法：采用酶联免疫法测定２６例多发性骨髓瘤（ＭＭ）、３４例急性白血病（ＡＬ）、１７例非霍奇金淋巴瘤（ＮＨＬ）患者化疗前后及正常献血员的血清ｓＩＬ－６Ｒ水平。结果：初诊时血清ｓＩＬ－６Ｒ水平，ＭＭ患者较正常对照组显著增高（Ｐ＜０．００１），Ｂ细胞系急性淋巴细胞白血病（Ｂ－ＡＬＬ）患者亦高于正常对照（Ｐ＜０．０１），急性非淋巴细胞白血病（ＡＮＬＬ）、Ｔ－ＡＬＬ、ＮＨＬ与正常对照无显著差异。血清ｓＩＬ－６Ｒ升高的初诊ＭＭ患者，其血清β２微球蛋白、肌酐水平显著高于ｓＩＬ－６Ｒ正常的ＭＭ患者（Ｐ＜０．００１，Ｐ＜０．０５），ＭＭ患者血清ｓＩＬ－６Ｒ水平不受临床分期影响。初诊Ｂ－ＡＬＬ患者的血清乳酸脱氢酶水平，血清ｓＩＬ－６Ｒ升高者显著高于ｓＩＬ－６Ｒ正常者（Ｐ＜０．０５）。初诊时ＭＭ患者血清ｓＩＬ－６Ｒ水平高低与化疗疗效有关，有效患者的血清ｓＩＬ－６Ｒ水平显著低于无效患者（Ｐ＜０．０５）。ＭＭ、Ｂ－ＡＬＬ患者化疗前后血清ｓＩＬ－６Ｒ的动态改变与病情活动有关，ｓＩＬ－６Ｒ水平与ＭＭ患者血清Ｍ蛋白、骨髓中浆细胞比例的变化相一致，Ｂ－ＡＬＬ患者完?
Objective: To investigate the clinical value of serum soluble interleukin 6 receptor (sIL-6R) in patients with hematologic malignancies. METHODS: Serum sIL-6R levels in 26 patients with multiple myeloma (MM), 34 patients with acute leukemia (AL), and 17 patients with non-Hodgkin lymphoma (NHL) before and after chemotherapy and normal blood donors were determined by enzyme-linked immunosorbent assay . RESULTS: Serum sIL-6R levels were significantly higher in newly diagnosed MM patients than in normal controls (P<0.001), and patients with B-cell acute lymphoblastic leukemia (B-ALL) were also higher than those in normal controls (P<0.01). ), Acute non-lymphocytic leukemia (ANLL), T-ALL, NHL and normal controls were not significantly different. Serum β2 microglobulin and creatinine levels were significantly higher in newly diagnosed MM patients with elevated serum sIL-6R than those in sIL-6R normal MM patients (P<0.001, P<0.05). Serum sIL-6R in MM patients The level is not affected by the clinical stage. Serum lactate dehydrogenase levels and serum sIL-6R levels in newly diagnosed B-ALL patients were significantly higher than those with normal sIL-6R levels (P<0.05). The level of serum sIL-6R in MM patients was related to the efficacy of chemotherapy. The serum sIL-6R levels in effective patients were significantly lower than those in ineffective patients (P<0.05). The dynamic changes of serum sIL-6R before and after chemotherapy in MM and B-ALL patients are related to the disease activity. The level of sIL-6R is consistent with the change of serum M protein and bone marrow plasma cell ratio in MM patients.